Multiple Sclerosis Clinical Trial

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

Summary

To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)

View Full Description

Full Description

The study is divided into a Core Phase, which includes the Double-Blind Treatment Period, and an Extension Phase in which all patients will be treated with fingolimod. The Core Phase is a 24-month, double-blind, randomized, active-controlled, parallel-group multicenter study phase to evaluate the efficacy and safety of fingolimod compared to IFN β-1a in children/adolescent patients aged 10-17 years old with MS. The Extension Phase is a 60-month (5 year) study phase for patients who complete the Core Phase of the study and meet all inclusion/exclusion criteria and for patients who will be recruited in the younger cohort to participate in the Extension Phase. The 'younger cohort' refers to the population of pediatric patients fulfilling any single one or a combination of the following criteria: being ≤12 years of age, or weighing ≤40 kg, or being prepubertal (i.e. pubertal status of Tanner stage <2). The recruitment of the younger cohort (up to 25 patients) was requested as a post- approval health authority commitment

View Eligibility Criteria

Eligibility Criteria

Key Inclusion Criteria Core Phase:

diagnosis of multiple sclerosis
at least one MS relapse during the previous year or two MS relapses in the previous 2 years or evidence of Gd enhancing lesions on MRI within 6 months EDSS score of 0 to 5.5, inclusive

Key Exclusion Criteria Core Phase:

patients with progressive MS
patients with an active, chronic disease of the immune system other than MS
patients meeting the definition of ADEM
patients with severe cardiac disease or significant findings on the screening ECG.
patients with severe renal insufficiency

Key Inclusion Criteria Extension Phase:

Applies to all patients participating in the Core Phase and then entering the Extension Phase. 1. Patients that originally met Core Phase Inclusion criteria and completed the Core phase on or off of study drug.

Applies to patients newly recruited to participate in the Extension Phase.

All newly recruited patients' that enroll directly into the Extension Phase must fulfill the local country health authority product label approved for pediatric age group for inclusion criteria.
Central review (including initial MRI report) of the diagnosis of pediatric MS will be required for all newly recruited patients.

Key Exclusion Criteria Extension Phase:

Applies to patients who completed the Core Phase, but prematurely discontinued study drug.

Premature discontinuation of the study drug during the Core Phase due to:

an adverse event,
serious adverse event,
laboratory abnormality
other conditions leading to permanent study drug discontinuation due to safety reasons
Patients with known new events or concomitant medications (washout periods required prior to Visit 15) that would exclude them from the Core Phase exclusion criteria. Serological or other additional tests will not be required.

Applies to patients newly recruited in the younger cohort to participate in the Extension Phase.

1. All newly recruited patients in the younger cohort that enroll directly into the Extension Phase must fulfill the exclusion criteria for the core phase.

Study is for people with:

Multiple Sclerosis

Phase:

Phase 3

Estimated Enrollment:

235

Study ID:

NCT01892722

Recruitment Status:

Recruiting

Sponsor:

Novartis Pharmaceuticals

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 107 Locations for this study

See Locations Near You

Novartis Investigative Site
Birmingham Alabama, 35294, United States
Novartis Investigative Site
Little Rock Arkansas, 72202, United States
Novartis Investigative Site
Los Angeles California, 90027, United States More Info
Martha E. Arellano-Garcia
Contact
323-361-5812
[email protected]
Novartis Investigative Site
San Francisco California, 94115, United States
Novartis Investigative Site
Aurora Colorado, 80045, United States
Novartis Investigative Site
Miami Florida, 33136, United States
Novartis Investigative Site
Orlando Florida, 32819, United States
Novartis Investigative Site
Tallahassee Florida, 32312, United States
Novartis Investigative Site
Chicago Illinois, 60611, United States
Novartis Investigative Site
Boston Massachusetts, 02114, United States
Novartis Investigative Site
Boston Massachusetts, 02115, United States
Novartis Investigative Site
Detroit Michigan, 48201, United States
Novartis Investigative Site
New Brunswick New Jersey, 08901, United States
Novartis Investigative Site
Rochester New York, 14642, United States
Novartis Investigative Site
Stony Brook New York, 11794, United States
Novartis Investigative Site
Chapel Hill North Carolina, 27599, United States
Novartis Investigative Site
Durham North Carolina, 27710, United States
Novartis Investigative Site
Philadelphia Pennsylvania, 19104, United States
Novartis Investigative Site
Greenville South Carolina, 29607, United States
Novartis Investigative Site
San Antonio Texas, 78229, United States
Novartis Investigative Site
Salt Lake City Utah, 84108, United States
Novartis Investigative Site
Parkville Victoria, 3052, Australia
Novartis Investigative Site
Vienna , 1090, Austria
Novartis Investigative Site
Minsk , 22011, Belarus
Novartis Investigative Site
Belo Horizonte Minas Gerais, 30150, Brazil
Novartis Investigative Site
Rio de Janeiro RJ, 20270, Brazil
Novartis Investigative Site
Sao Paulo SP, 05403, Brazil
Novartis Investigative Site
Goiania , 74605, Brazil
Novartis Investigative Site
Sofia , 1113, Bulgaria
Novartis Investigative Site
Calgary Alberta, T3B 6, Canada
Novartis Investigative Site
Ottawa Ontario, K1H 8, Canada
Novartis Investigative Site
Osijek , 31000, Croatia
Novartis Investigative Site
Tallinn , 10617, Estonia
Novartis Investigative Site
Bordeaux Cedex , 33076, France
Novartis Investigative Site
Le Kremlin Bicetre , 94275, France
Novartis Investigative Site
Marseille Cedex 05 , 13885, France
Novartis Investigative Site
Montpellier , 34295, France
Novartis Investigative Site
Toulouse Cedex , 31059, France
Novartis Investigative Site
Bochum , 44791, Germany
Novartis Investigative Site
Bonn , 53111, Germany
Novartis Investigative Site
Dresden , 01307, Germany
Novartis Investigative Site
Erlangen , 91054, Germany
Novartis Investigative Site
Essen , 45147, Germany
Novartis Investigative Site
Freiburg , 79106, Germany
Novartis Investigative Site
Gottingen , 37075, Germany
Novartis Investigative Site
Hamburg , 20246, Germany
Novartis Investigative Site
Muenchen , 80337, Germany
Novartis Investigative Site
Muenster , 48149, Germany
Novartis Investigative Site
Bari BA, 70124, Italy
Novartis Investigative Site
Montichiari BS, 25018, Italy
Novartis Investigative Site
Catania CT, 95123, Italy
Novartis Investigative Site
Milano MI, 20132, Italy
Novartis Investigative Site
Cefalu PA, 90015, Italy
Novartis Investigative Site
Roma RM, 00133, Italy
Novartis Investigative Site
Roma RM, 00189, Italy
Novartis Investigative Site
Gallarate VA, 21013, Italy
Novartis Investigative Site
Napoli , 80131, Italy
Novartis Investigative Site
Riga , LV-10, Latvia
Novartis Investigative Site
Kaunas LTU, LT 50, Lithuania
Novartis Investigative Site
Ciudad De Mexico D F, 06700, Mexico
Novartis Investigative Site
Mexico Distrito Federal, 03310, Mexico
Novartis Investigative Site
Mexico Distrito Federal, 04530, Mexico
Novartis Investigative Site
Mexico Distrito Federal, 06720, Mexico
Novartis Investigative Site
Merida Yucatán, 97125, Mexico
Novartis Investigative Site
Rotterdam , 3015 , Netherlands
Novartis Investigative Site
Lodz , 93-33, Poland
Novartis Investigative Site
Lublin , 20-09, Poland
Novartis Investigative Site
Poznan , 60-35, Poland
Novartis Investigative Site
Wroclaw , 50 42, Poland
Novartis Investigative Site
Santurce , 00912, Puerto Rico
Novartis Investigative Site
Bucuresti , 04191, Romania
Novartis Investigative Site
Kazan , 42004, Russian Federation
Novartis Investigative Site
Moscow , 11960, Russian Federation
Novartis Investigative Site
Moscow , 11999, Russian Federation
Novartis Investigative Site
Novosibirsk , 63008, Russian Federation
Novartis Investigative Site
St. Petersburg , 19711, Russian Federation
Novartis Investigative Site
Belgrade , 11000, Serbia
Novartis Investigative Site
Kragujevac , 34000, Serbia
Novartis Investigative Site
Novi Sad , 21000, Serbia
Novartis Investigative Site
Bratislava Slovensko, 83340, Slovakia
Novartis Investigative Site
Malaga Andalucia, 29010, Spain
Novartis Investigative Site
Sevilla Andalucia, 41009, Spain
Novartis Investigative Site
Esplugues De Llobregat Barcelona, 08950, Spain
Novartis Investigative Site
Barcelona Catalunya, 08035, Spain
Novartis Investigative Site
Valencia Comunidad Valenciana, 46010, Spain
Novartis Investigative Site
Barakaldo Pais Vasco, 48903, Spain
Novartis Investigative Site
Vigo Pontevedra, 36212, Spain
Novartis Investigative Site
Madrid , 28006, Spain
Novartis Investigative Site
Madrid , 28034, Spain
Novartis Investigative Site
Lund , 221 8, Sweden
Novartis Investigative Site
Istanbul TUR, 34098, Turkey
Novartis Investigative Site
Ankara , 06100, Turkey
Novartis Investigative Site
Ankara , 06500, Turkey
Novartis Investigative Site
Izmir , 35340, Turkey
Novartis Investigative Site
Konak-Izmir , 35210, Turkey
Novartis Investigative Site
Samsun , 55139, Turkey
Novartis Investigative Site
Cherkasy , 18000, Ukraine
Novartis Investigative Site
Dnipropetrovsk , 49027, Ukraine
Novartis Investigative Site
Kharkiv , 61068, Ukraine
Novartis Investigative Site
Kharkiv , 61091, Ukraine
Novartis Investigative Site
Kiev , 03110, Ukraine
Novartis Investigative Site
Lviv , 79010, Ukraine
Novartis Investigative Site
Odesa , 65009, Ukraine
Novartis Investigative Site
Vinnytsa , 21029, Ukraine
Novartis Investigative Site
West Midlands Birmingham, B4 6N, United Kingdom
Novartis Investigative Site
Edinburgh , EH9 1, United Kingdom
Novartis Investigative Site
London , WC1N , United Kingdom
Novartis Investigative Site
London , WC1N , United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Phase:

Phase 3

Estimated Enrollment:

235

Study ID:

NCT01892722

Recruitment Status:

Recruiting

Sponsor:


Novartis Pharmaceuticals

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.